公开(公告)号：US20140080886A1

公开(公告)日：2014-03-20

申请号：US14029333

申请日：2013-09-17

Applicant: AbbVie Inc.

Inventor： Tami J. Pilot-Matias ,  Preethi Krishnan ,  Warren M. Kati ,  Christine A. Collins ,  Neeta C. Mistry ,  Clarence J. Maring ,  David A. DeGoey ,  John K. Pratt ,  Dachun Liu ,  Rolf Wagner

IPC: A61K31/4025 ,  A61K45/06

CPC classification number: A61K31/4025 ,  A61K31/401 ,  A61K45/06 ,  A61K2300/00

Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.

公开(公告)号：US10201584B1

公开(公告)日：2019-02-12

申请号：US14247975

申请日：2014-04-08

Applicant: AbbVie Inc.

Inventor： Christine A. Collins ,  Daniel E. Cohen ,  Gennadiy Koev ,  Preethi Krishnan ,  Tami J. Pilot-Matias

IPC: A01N37/18 ,  A61K38/00 ,  A61K31/33 ,  A61K31/00 ,  A61K31/505 ,  A61K31/435 ,  A61K31/44 ,  A61K31/41 ,  A61K31/40 ,  A61K31/27 ,  A61K31/16 ,  A01N43/00 ,  A01N43/58 ,  A01N43/54 ,  A01N43/40 ,  A01N43/42 ,  A01N43/64 ,  A01N43/36 ,  A01N43/38 ,  A01N47/10 ,  A01N41/02 ,  C07D471/04 ,  C07D471/22 ,  C07D487/04 ,  A61P1/16 ,  A61K38/05 ,  A61K31/513 ,  A61K45/06

Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

公开(公告)号：US20190167684A1

公开(公告)日：2019-06-06

申请号：US16272599

申请日：2019-02-11

Applicant: AbbVie Inc.

Inventor： Christine A. Collins ,  Daniel E. Cohen ,  Gennadiy Koev ,  Preethi Krishnan ,  Tami J. Pilot-Matias

IPC: A61K31/513 ,  A01N37/18 ,  A61K45/06 ,  A61K31/4025 ,  A61K38/05 ,  A61K38/00

Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

公开(公告)号：US20170360783A1

公开(公告)日：2017-12-21

申请号：US15693963

申请日：2017-09-01

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolado M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20250059280A1

公开(公告)日：2025-02-20

申请号：US18806311

申请日：2024-08-15

Applicant: AbbVie Inc.

Inventor： Ana Gabriela Pires dos Santos ,  Preethi Krishnan ,  Mong-Jen Chen ,  Aline Goebel ,  Neha Thakre ,  Insa Winzenborg ,  Tanaya Vaidya

IPC: C07K16/28 ,  A61K9/00 ,  A61P31/18

Abstract: The invention described herein relates to methods of treating HIV infection comprising administering an anti-PD-1 monoclonal antibody and/or an anti-α4β7 monoclonal antibody.

公开(公告)号：US11639390B2

公开(公告)日：2023-05-02

申请号：US17378565

申请日：2021-07-16

Applicant: AbbVie Inc.

Inventor： Jing Min ,  Teresa (Iok-Chan) Ng ,  Lorenzo Benatuil ,  Jacqueline Bixby ,  Tatyana Dekhtyar ,  Feng Dong ,  Axel Hernandez, Jr. ,  Preethi Krishnan ,  Liangjun Lu ,  Federico Mensa ,  Renee Miller ,  Gautam Sahu

IPC: C12N5/02 ,  C12N5/20 ,  C12N1/20 ,  C12N15/00 ,  C07K16/46 ,  C07K16/00 ,  C07H21/04 ,  C07K16/28 ,  A61P31/18 ,  C12N15/63 ,  A61K39/00

Abstract: The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.

公开(公告)号：US20220017624A1

公开(公告)日：2022-01-20

申请号：US17378565

申请日：2021-07-16

Applicant: AbbVie Inc.

Inventor： Jing Min ,  Teresa (Iok-Chan) Ng ,  Lorenzo Benatuil ,  Jacqueline Bixby ,  Tatyana Dekhtyar ,  Feng Dong ,  Axel Hernandez, Jr. ,  Preethi Krishnan ,  Liangjun Lu ,  Federico Mensa ,  Renee Miller ,  Gautam Sahu

IPC: C07K16/28 ,  A61P31/18 ,  C12N15/63

Abstract: The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection.

公开(公告)号：US20200330460A1

公开(公告)日：2020-10-22

申请号：US16643069

申请日：2018-08-30

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Frederico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolando M. Viani ,  Stanley Wang ,  Zhenzhan Zhang

IPC: A61K31/4985 ,  A61K31/454 ,  A61K31/7072 ,  A61K31/498

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10201541B1

公开(公告)日：2019-02-12

申请号：US15398390

申请日：2017-01-04

Applicant: AbbVie Inc.

Inventor： Christine A. Collins ,  Daniel E. Cohen ,  Gennadiy Koev ,  Preethi Krishnan ,  Tami J. Pilot-Matias

IPC: A01N37/18 ,  A61K38/00 ,  A61K31/33 ,  A61K31/00 ,  A61K31/505 ,  A61K31/435 ,  A61K31/44 ,  A61K31/41 ,  A61K31/40 ,  A61K31/27 ,  A61K31/16 ,  A01N43/00 ,  A01N43/58 ,  A01N43/54 ,  A01N43/40 ,  A01N43/42 ,  A01N43/64 ,  A01N47/10 ,  A01N41/02 ,  C07D471/04 ,  C07D471/22 ,  C07D487/04 ,  A61P1/16 ,  A61K31/513 ,  A61K31/4025 ,  A61K45/06 ,  A61K38/05

Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.

公开(公告)号：US09249138B2

公开(公告)日：2016-02-02

申请号：US14017901

申请日：2013-09-04

Applicant: ABBVIE INC.

Inventor： David A. Degoey ,  Pamela L. Donner ,  Warren M. Kati ,  Charles W. Hutchins ,  Allan C. Krueger ,  John T. Randolph ,  Christopher E. Motter ,  Preethi Krishnan ,  Neeta C. Mistry ,  Tami J. Pilot-Matias ,  Sachin V. Patel ,  Xiaoyan Li ,  Todd N. Soltwedel ,  Lissa T. Nelson

IPC: C07D239/48 ,  C07D471/04

CPC classification number: C07D471/04 ,  C07D239/48

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.